Form 4: Cartesian Therapeutics Grants Equity to Director Adrian Bot

Cartesian Therapeutics, Inc. granted 5,800 Restricted Stock Units and 17,200 stock options to Director Adrian Ion Bot, with vesting scheduled through December 2028.

Summary

• Adrian Ion Bot, a Director of Cartesian Therapeutics, Inc. (RNAC), was granted equity awards.
• The awards include 5,800 Restricted Stock Units (RSUs) and 17,200 stock options.
• The transaction date for these grants was December 16, 2025.
• Each RSU represents a contingent right to receive one share of common stock, with a price of $0.
• The RSUs will vest in three equal annual installments, becoming fully vested on December 16, 2028.
• The stock options have an exercise price of $8.29 per share.
• The stock options will vest in 36 equal monthly installments, becoming fully vested on December 16, 2028.
• Following these transactions, Adrian Ion Bot beneficially owns 5,800 shares of common stock (from RSUs) and 17,200 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive as it aligns director interests with shareholders, which is generally viewed favorably, though it introduces potential future dilution.

Positives

• The equity grants align the interests of Director Adrian Ion Bot with those of the shareholders, incentivizing long-term performance.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders when the RSUs vest and options are exercised.

Risks

• Potential future dilution from the vesting and exercise of the granted equity awards.
• The value of the compensation is tied to the company's stock performance, exposing the director to market risk.

Future Outlook

The equity grants, with their multi-year vesting schedules extending to December 2028, indicate a long-term incentive structure for Director Adrian Ion Bot, aligning his future financial interests with the company's performance over the coming years.

Industry Context

Equity compensation, including Restricted Stock Units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, including directors. This grant is consistent with typical compensation structures aimed at aligning leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The use of both Restricted Stock Units (RSUs) and stock options is a common hybrid approach for executive and director compensation in the biotech sector, balancing immediate value (RSUs) with performance-based upside (options).
• Multi-year vesting schedules, such as the three-year annual vesting for RSUs and 36-month monthly vesting for options, are standard in the industry to promote long-term retention and performance.
• The exercise price of $8.29 for the stock options is likely based on the market price of Cartesian Therapeutics, Inc. (RNAC) common stock on the grant date, which is a typical practice for incentive stock options.

Corporate Governance

Related Party Transactions

• Grant of 5,800 Restricted Stock Units and 17,200 Stock Options to Adrian Ion Bot, a Director of Cartesian Therapeutics, Inc. This is a transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of equity awards; however, the grants are intended to align director incentives with long-term shareholder value creation.
• Director (Adrian Ion Bot): Receives significant equity compensation, tying personal wealth directly to the company's stock performance and providing a strong incentive for long-term commitment and performance.

Next Steps

• The Restricted Stock Units will vest in three equal annual installments following December 16, 2025, with full vesting by December 16, 2028.
• The Stock Options will vest in 36 equal monthly installments following December 16, 2025, with full vesting by December 16, 2028.

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Adrian Ion Bot, Vesting